SAMSUNG-SEMICONDUCTOR
23.12.2021 10:02:09 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that it has developed the PM1743 SSD for enterprise servers, integrating the PCIe (Peripheral Component Interconnect Express) 5.0 interface with Samsung's advanced sixth-generation V-NAND.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005139/en/
"For over a decade, Samsung has been delivering SATA, SAS and PCIe-based SSDs that have been recognized for outstanding performance and reliability by leading enterprise server customers including corporations, governments and financial institutions," said Yong Ho Song, Executive Vice President and Head of the Memory Controller Development Team at Samsung Electronics. "The introduction of our PCIe 5.0 SSD, along with PCIe 6.0-based product developments that are underway, will further solidify our technological leadership in the enterprise server market."
"Intel has been working with Samsung to test Samsung's newest PCIe NVMe SSD, the PM1743. Together, we have jointly resolved complicated technical issues encountered with PCIe 5.0 during this initial evaluation period. The performance potential of Gen5 is truly impressive. In the near future, we strongly believe that PCIe Gen5 systems with high-speed NVMe SSDs will have the ability to transform applications such as AI/ML and high-performance databases," said Jim Pappas, Director, Technology Initiatives, Intel Corporation. "Looking ahead, we are confident that Intel and Samsung's continued commitment in industry leadership will provide these and other benefits to our mutual customers."
PCIe 5.0 offers a bandwidth of 32 gigatransfers per second (GT/s), doubling that of PCIe 4.0. Leveraging a proprietary controller designed to support the latest PCIe standard, the PM1743 will deliver outstanding read and write speeds to accommodate the rapidly increasing performance requirements of data centers.
Samsung’s PM1743 will feature a sequential read speed of up to 13,000 megabytes per second (MB/s) and a random read speed of 2,500K input/output operations per second (IOPS), offering 1.9x and 1.7x faster speeds over the previous PCIe 4.0-based products. Moreover, write speeds have been elevated significantly, with a sequential write speed of 6,600 MB/s and a random write speed of 250K IOPS, also delivering 1.7x and 1.9x faster speeds, respectively. These remarkable data transfer rates will allow enterprise server manufacturers deploying the PM1743 to enjoy a much higher level of performance.
In addition, the new SSD can provide improved power efficiency of up to 608 MB/s per watt, which represents about a 30% boost over the previous generation. This is expected to lower server and data center operating costs significantly, while also helping to reduce their carbon footprint.
Available in a wide variety of capacities from 1.92 terabytes (TB) to 15.36TB, the PM1743 will be offered in the conventional 2.5-inch form factor, as well as in a 3-inch EDSFF (E3.S) — an increasingly popular SSD form factor designed specifically for next-generation enterprise servers and data centers. Customers deploying 7.5mm EDSFF SSDs will be able to double the storage density in their systems, compared to when the 15mm 2.5-inch form factor is used. Coupled with excellent signal integrity and thermal efficiency, the EDSFF is ideal for most PCIe 5.0 enterprise solutions.
Furthermore, the PM1743 is expected to be the industry's first PCIe 5.0 SSD with dual-port support, guaranteeing server operational stability and high availability when a connection to one port fails.
Recently, the importance of data security has been growing stronger in the enterprise server market. To ensure that these needs are addressed, Samsung's PM1743 will implement advanced security features that were traditionally only available at the server level. By embedding a security processor and Root of Trust (RoT), the SSD will protect against security threats and data forgery to provide data confidentiality and integrity, while also enabling Secure Boot in server systems through attestation.
Samsung is now delivering samples of the PM1743 to global chipset and server manufacturers for joint system development. The company plans to begin mass producing the PM1743 in the first quarter of 2022, as it continues to foster a highly robust ecosystem for the new PCIe 5.0 standard.
The PM1743 has been designated a CES 2022 Innovation Awards Honoree in the category of Computer Hardware & Components.
###
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005139/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom